摘要
以3-硝基苯酚为原料,经过醚化反应,与1-(2,3-二氯苯基)哌嗪盐酸盐或1-(苯并[b]噻吩基)哌嗪盐酸盐进行N-烷基化反应,分别制得1-(2,3-二氯苯基)-4-[4-(3-硝基苯氧基)丁基]哌嗪(5a)或1-(苯并[b]噻吩基)-4-[4-(3-硝基苯氧基)丁基]哌嗪(5b)。5a或5b分别经电还原反应,制得抗精神病药物阿立哌唑中间体1-(2,3-二氯苯基)-4-[4-(3-氨基苯氧基)丁基]哌嗪(3a)和布瑞哌唑中间体1-(苯并[b]噻吩基)-4-[4-(3-氨基苯氧基)丁基]哌嗪(3b),还原反应收率分别为93%和97%。
1-(2,3-Dichlorophenyl)-4-[4-(3-nitrophenoxy)butyl]piperazine(5a)or 1-(benzo[b]thiophenyl)-4-[4-(3-nitrophenoxy)butyl]piperazine(5b)were prepared from 3-nitrophenol by etherification,and then N-alkylation reaction with 1-(2,3-dichlorophenyl)piperazine hydrochloride or 1-(benzo[b]thiophenyl)piperazine hydrochloride.The intermediate of aripiprazole or brexpiprazole,1-(2,3-dichlorophenyl)-4-[4-(3-aminophenoxy)butyl]piperazine(3a)or 1-(benzo[b]thiophenyl)-4-[4-(3-aminophenoxy)butyl]piperazine(3b)were prepared by electroreduction reactions of 5a or 5b with yields of 93%and 97%,respectively.
作者
何嘉宸
曾顺
彭泽根
杨贞皓
胡艾希
HE Jiachen;ZENG Shun;PENG Zegen;YANG Zhenhao;HU Aixi(College of Chemistry and Chemical Engineering,Hunan University,Changsha 410082;Hunan Xiangzhong Pharmaceutical Co.,Ltd.,Shaoyang 422000)
出处
《中国医药工业杂志》
CAS
CSCD
北大核心
2023年第3期347-350,356,共5页
Chinese Journal of Pharmaceuticals
关键词
阿立哌唑
布瑞哌唑
中间体
电还原
工艺改进
aripiprazole
brexpiprazole
intermediate
electroreduction
process improvement